ClinicalTrials.gg
Not yet recruitingNCT07413081PACE-ATTRUpdated Feb 17, 2026

Increased Pacemaker Lower Rate in ATTR Cardiac Amyloidosis

An interventional study of Increasing the pacemaker lower rate and Standard setting in Cardiac Amyloidosis and Pacemaker, sponsored by Region Skane. Not yet recruiting at 9 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Region Skane · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Amyloid Neuropathies, Familial with a site in Sweden — 3 open to participants now, 3 under way, 1 of them phase 3. Amyloid Neuropathies, Familial · Sweden.

Planned enrollment
11th of 12
34 · median 168
Started
2026
the only one that year
No phase
Only one
of the 13
Registered
13th of 13
by date
Lead sponsor
1 of 13
Region Skane

Among the 13 studies in Amyloid Neuropathies, Familial with a site in Sweden, this one is the 11th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2026, is the only one with no phase, and was the 13th registered.

Amyloid Neuropathies, Familial

188 studies on the registry are indexed under Amyloid Neuropathies, Familial; 94 are open to participants now.

Browse Amyloid Neuropathies, Familial studies →

Open to participants now

3 of the 13 studies in Amyloid Neuropathies, Familial with a site in Sweden are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 69 Amyloid Neuropathies, Familial studies recruiting now, 53 (77%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Amyloid Neuropathies, Familial with a site in Sweden, or all of them as a file.
02

Study summary

In cardiac amyloidosis, the heart muscle becomes thick and stiff, making it difficult to pump enough blood with each beat. The heart also often cannot increase its stroke volume, making patients with cardiac amyloidosis more dependent on having an adequate heart rate. Many develop conduction problems and need a pacemaker. In a related condition, heart failure with preserved ejection fraction, setting a higher pacemaker rate improved patients' quality of life. It is not known if the same benefits apply to amyloidosis. This study will test whether raising the pacemaker rate improves well-being and daily function in affected patients.

Read the detailed description

Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly recognized cause of restrictive cardiomyopathy, characterized by reduced ventricular compliance, low stroke volume, and marked dependence on heart rate for maintenance of cardiac output. Conduction disease is common in ATTR-CM, and a substantial proportion of patients require permanent pacemaker implantation.

Although disease-modifying therapy can slow disease progression, evidence guiding optimization of pacemaker therapy in ATTR-CM is lacking. In heart failure with preserved ejection fraction, a condition also characterized by reduced ventricular compliance, increased pacemaker lower rate settings have been shown to improve functional capacity and quality of life. However, patients with cardiac amyloidosis were excluded from these studies. Consequently, current practice in ATTR-CM relies largely on extrapolation and expert opinion.

In this randomized multicenter 2×2 crossover trial, we aim to determine whether a higher pacemaker lower rate (80 bpm) improves health-related quality of life (QoL) and functional capacity in patients with ATTR-CM compared with the standard setting of 60 bpm.

03

Conditions studied

  • Cardiac Amyloidosis
  • Pacemaker
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ATTR-CM defined as one of the following:
  • a.Positive cardiac for ATTR amyloidosis
  • b.Positive extra-cardiac biopsy for ATTR amyloidosis AND cardiac involvement demonstrated by CMR or echocardiography
  • c.Grade 2-3 uptake on DPD-scintigraphy AND negative serum free light chain and negative urine and serum immunofixation AND cardiac involvement demonstrated by CMR or echocardiography
  • Ongoing treatment with a transthyretin stabilizer or silencer OR considered not to be a candidate for these therapies with no planned initiation during the study period.
  • functional class II-III
  • Pre-existing pacemaker and either:
  • a.Atrial pacing with minimal RV pacing (\<2%), or
  • b.His bundle or left bundle branch area pacing, or
  • c.Biventricular pacing, or
  • d.Ongoing RV pacing with a high degree of RV pace (>80%)
  • NT-proBNP >600 ng/L
  • Age ≥18 years
  • Ability and willingness to provide written
  • Pacing >80% with a programmed lower rate of 60 (AAI/CSP/CRT/RV-pace)

Exclusion criteria

Exclusion Criteria:

  • Inability to perform the 6-minute walk test.
  • Planned coronary revascularization, ablation of atrial flutter/fibrillation, or any severe (obstructive or regurgitant) valvular heart disease expected to require intervention during the trial in the investigator's opinion.
  • MI, unstable angina, coronary revascularization (percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)), ablation of atrial flutter/fibrillation, cardioversion, valve repair/replacement, hospitalization for decompensated heart failure or cardiac resynchronisation therapy within 12 weeks prior to enrollment.
  • Planned upgrade to CRT or conduction system pacing in patients with RV pacing.
  • More than moderate valvular stenosis or regurgitation
  • Inability of the patient, in the opinion of the investigator, to understand and/or comply with procedures and/or follow-up OR any conditions that, in the opinion of the investigator, may render the patient unable to complete the study
  • Presence of any other disease than heart failure with a of \< 1year in the investigators opinion
  • Enrollment in other interventional device or drug trials during the study period, with the exception of open label extension studies
  • Listed for cardiac transplantation
  • Initiation of SGLT2-inhibitor or mineralocorticoid receptor antagonist within 4 weeks prior to enrollment
  • Initiation or change in loop diuretic therapy within 4 weeks prior to enrollment
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
34 participants (estimated)

Study arms

  • Active comparator
    80 bpm

    Device: Increasing the pacemaker lower rate

  • Other
    60 bpm

    Device: Standard setting

Interventions

  • DeviceIncreasing the pacemaker lower rate

    Increasing the pacemaker lower rate from 60 to 80 bpm

  • DeviceStandard setting

    Lower rate setting of 60 bpm

06

What researchers measure

Primary outcomes

  1. Minnesota Living with Heart Failure Questionnaire (MLHFQ)

    The MLHFQ is a validated patient-reported outcome assessing heart failure-related quality of life. It consists of 21 items scored 0-5, yielding a total score range of 0-105. Higher scores indicate worse quality of life. MLHFQ is collected at Visits 1-4.

    Time frame: End of each treatment period (Visit 2 at approximately 3 months and Visit 4 at approximately 7 months)

Secondary outcomes

  1. Distance walked during the 6-Minute Walk Test (6MWT)

    The 6-Minute Walk Test measures the distance walked in meters during six minutes on a flat, hard surface. The distance walked ranges from 0 meters upward, with higher distances indicating better functional capacity. The 6MWT is performed at Visits 1-4.

    Time frame: End of each treatment period (Visit 2 at approximately 3 months and Visit 4 at approximately 7 months)

  2. Levels of N-terminal pro-B-type Natriuretic Peptide (NT-proBNP)

    NT-proBNP is a circulating biomarker of myocardial wall stress and heart failure severity. It is measured in pg/mL. Higher concentrations indicate worse cardiac function. NT-proBNP is assessed at Visits 1-4.

    Time frame: End of each treatment period (Visit 2 at approximately 3 months and Visit 4 at approximately 7 months)

  3. New York Heart Association (NYHA) Functional Class

    NYHA functional class is a measure of heart failure severity ranging from Class I to Class IV, with higher class indicating worse functional status. NYHA class is assessed at Visits 1-4.

    Time frame: End of each treatment period (Visit 2 at approximately 3 months and Visit 4 at approximately 7 months)

  4. National Amyloidosis Centre (NAC) Stage

    National Amyloidosis Centre (NAC) stage is a prognostic staging system for transthyretin cardiac amyloidosis based on cardiac biomarkers. It is categorized as Stage I, II, or III, with higher stage indicating more advanced disease. NAC stage is assessed at Visits 1-4.

    Time frame: End of each treatment period (Visit 2 at approximately 3 months and Visit 4 at approximately 7 months)

  5. Number of participants with hospitalization or urgent outpatient visit for atrial fibrillation

    This outcome captures atrial fibrillation-related hospitalizations or urgent outpatient visits occurring during each treatment period.

    Time frame: During each treatment period (approximately 3 months per period)

  6. Atrial fibrillation burden assessed by implanted pacemaker

    Atrial fibrillation (AF) burden is defined as the percentage of time spent in atrial fibrillation, as recorded by the implanted pacemaker's arrhythmia detection algorithms. Higher values indicate greater arrhythmia burden.

    Time frame: During each treatment period (approximately 3 months per period)

  7. Physical activity level assessed by implanted pacemaker

    Physical activity is assessed using the implanted pacemaker's built-in activity sensor. Higher values indicate greater physical activity.

    Time frame: During each treatment period (approximately 3 months per period)

  8. Levels of High-Sensitivity Cardiac Troponin (hs-cTn)

    High-sensitivity cardiac troponin (hs-cTn) is a biomarker of myocardial injury. It is measured in ng/L in plasma. Higher concentrations indicate greater myocardial injury. hs-cTn is assessed at Visits 1-4.

    Time frame: End of each treatment period (Visit 2 at approximately 3 months and Visit 4 at approximately 7 months)

Other outcomes

  1. Number of participants with hospitalization or urgent outpatient visit for heart failure

    This outcome captures heart failure-related hospitalizations or urgent outpatient visits occurring during each treatment period.

    Time frame: During each treatment period (approximately 3 months per period)

  2. Daily loop diuretic dose

    Daily loop diuretic dose is recorded as milligrams per day. Higher doses indicate greater diuretic requirement. Loop diuretic dosing is assessed at Visits 1-4.

    Time frame: End of each treatment period (Visit 2 at approximately 3 months and Visit 4 at approximately 7 months)

  3. Number of participants with cardiac death

    Cardiac death is defined as death resulting from cardiovascular causes, including heart failure, arrhythmia, or sudden cardiac death, as assessed by the site investigator.

    Time frame: Through study completion (up to approximately 7 months)

  4. Left Ventricular Ejection Fraction (LVEF)

    Left ventricular ejection fraction (LVEF) is expressed as a percentage (%). Higher values indicate better systolic function. LVEF is assessed by echocardiography at Visits 1-4.

    Time frame: End of each treatment period (Visit 2 at approximately 3 months and Visit 4 at approximately 7 months)

07

Study locations

9 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2026; primary completion for Dec 2027, 22 months later.

Of 30 interventional studies with no phase under Amyloid Neuropathies, Familial, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 67. This study's planned 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2026
First posted
Feb 17, 2026
StartEst.
Feb 1, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07413081
Lead sponsor
Region Skane
Responsible party
Sponsor
First posted
Feb 17, 2026
Start date
Feb 1, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Feb 17, 2026

Study contacts

Arash Mokhtari, MD, PhD
Contact
arash.mokhtari.0561@med.lu.se
+4646171000

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion